Evidence map›Paper›PMID 35669849›Full record

ReviewProceedings of the National Academy of Sciences, India. Section B2022

COVID-19 Diagnostics: A Panoramic View on Its Present Scenario, Challenges and Solutions.

Marzuqa Quraishi, Shailja Kant Upadhyay, Anshul Nigam

Open access · hybridAbstract readReview
In one paragraph

Review in Proceedings of the National Academy of Sciences, India. Section B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marzuqa Quraishi *Amity Institute of Biotechnology, Amity University, Mumbai, Maharashtra 410206 India.ORCID 0000-0001-7784-6889
Shailja Kant Upadhyay *Amity Institute of Biotechnology, Amity University, Mumbai, Maharashtra 410206 India.
Anshul NigamAmity Institute of Biotechnology, Amity University, Mumbai, Maharashtra 410206 India.ORCID 0000-0002-4917-789X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The initial strategy to curb the surge of novel coronavirus disease, COVID-19, is prevention and quarantine, which are dependent on early diagnosis. The latest commercial diagnostic methods include AI/ML-based imaging methods and laboratory diagnosis, which differ in their efficiency. The former requires lung imaging and is useful for last stage patients. It was ensured to overcome the limitation of availability of laboratory-based kits, while the latter involves the collection of the suitable sample from an individual (blood sample, nasal or oral swab). Laboratory methods include methods like RT-PCR which is contemporarily contemplated as the benchmark for its quick and efficient SARS-CoV-2 infection detection. Other diagnosis alternatives include Serum Viral Neutralization (SVN) assays involving antigen-antibody reaction with much lower efficiency contrasted to RT-PCR. Apart from these methods, early detection has been key to the treatment of COVID-19, but the lack of sensitive assays to detect low viral titers acts as an impediment. This review presents an overview of detecting COVID-19 with the aid of several diagnostic techniques along with their benefits and limitations.

Indexed as

Computed tomographyCOVID-19CRISPR-Cas13a assayDiagnosticsELISART-PCR

Identifiers

PMID35669849
PMCPMC9137266
OpenAlexW4281685320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.